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Objective: Thrombolysis and open surgical revascularization are current options for the treatment of acute limb ischemia
(ALI). Despite the several randomized controlled trials comparing the two options, no single treatment can yet be rec-
ommended as a universal initial management of ALI. The purpose of this study was to evaluate contemporary endo-
vascular and surgical revascularization for ALI.
Methods: Consecutive patients with ALI treated with endovascular revascularization (ER) or open revascularization (OR)
between 2005 and 2011 were identiﬁed and reviewed. Procedural success and outcomes were compared between the two
groups. Limb salvage and survival were assessed by time-to-event methods, including Kaplan-Meier estimation and
competing-risks regression models.
Results: A total of 154 limbs were treated in 147 patients in the ER group, compared with 326 limbs in 296 patients in the
OR group. The mean follow-up was 14 6 18.5 months. The majority of patients presented with Rutherford II ischemia
(83% for OR, 90% for ER). In Rutherford II patients, technical success was achieved in 90.7% of the OR group vs 79.9%
of the ER group (P[ .002), with amputation rates of 10.0% vs 7.2% (P[ .35) at 30 days and 16.3% vs 13.0% (P[ .37)
at 1 year, respectively. In Rutherford II patients with failed bypass graft, technical success rate was 95.0% (OR) vs 75.0%
(ER) (P[ .001), whereas the amputation rate was 6.3% vs 15.38% (P[ .13) at 30 days and 24.1% vs 23.1% (P[ .90) at
1 year, respectively. The overall 30-day mortality rate was 13.2% (OR) and 5.4% (ER) (P [ .012). Overall amputation
rates were 13.5% (OR) vs 6.5% (ER) at 30 days (P [ .023) and 19.6% (OR) vs 13.0% (ER) at 1 year (P [ .074). The
primary patency rate was 57% (OR) and 51% (ER) at 1 year (P [ .74). Predictors of limb loss by life-table analysis
included coronary artery disease (hazard ratio [HR], 2.0; P[ .007) and Rutherford category III (HR, 19.0; P < .001).
Predictors of death by life-table analysis included age (HR, 1.03; P < .001), end-stage renal disease (HR, 7.28; P < .001),
cancer (HR, 1.65; P [ .005), and chronic obstructive pulmonary disease (HR, 1.61; P [ .005).
Conclusions: In patients presenting with class II ALI, ER or surgical OR resulted in comparable limb salvage rates.
Although technical success is higher with OR for patients presenting with failed bypass grafts, the amputation rates
are comparable. Overall mortality rates are signiﬁcantly higher at 30 days and 1 year in the OR group. (J Vasc Surg
2015;61:147-54.)Large randomized controlled trials have reported The development of advanced thrombolysis techniques
several advantages to thrombolysis for the treatment of
acute limb ischemia (ALI), including decreased amputation
rates, improved amputation-free survival, shorter hospital
admission,1 and decreased subsequent requirements for sur-
gical revascularization.2 Consequently, catheter-directed
thrombolysis (CDT) has been proposed as an alternative
to surgical revascularization as an initial treatment of ALI
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://dx.doi.org/10.1016/j.jvs.2014.06.109such as pharmacomechanical thrombolysis (PMT) and the
use of newer pharmacologic agents have helped achieve a
more complete and faster clot lysis while shortening the
duration of lysis.4 However, the risk of life-threatening
bleeding,5 including intracranial hemorrhage,1 and the
necessity for intensive care monitoring remain serious
tradeoffs to be considered in use of thrombolytic therapy.
Given the absence of contemporary outcomes
comparing surgery with lysis by current devices and pharma-
cologic agents for the treatment of ALI,6 the aim of this
study was to assess the comparative effectiveness of surgical
revascularization vs CDT with or without PMT in terms of
clinical efﬁcacy and safety as initial options in the treatment
of thromboembolic acute lower extremity ischemia.
METHODS
This study is a retrospective single-institutional review
of the prospectively maintained vascular registry at the Uni-
versity of Pittsburgh Medical Center. The study protocol
was approved by the Institutional Review Board of the
University of Pittsburgh. No study speciﬁc consent was147
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study received an exempt status. All patients gave informed
consent to undergo the procedures listed.
Patients. The study included all patients with lower ex-
tremity ALI who underwent endovascular revascularization
(ER) or open revascularization (OR) at the University of
Pittsburgh Medical Center from January 2005 through
May 2011. All procedures were performed by vascular sur-
geons. Procedural success, complications, and limb and over-
all outcome data were compared between the two groups.
Only patients with ALI due to embolism or thrombosis
of a native artery, bypass graft, or previous stent were
considered in the study. Blue toe syndrome and acute
ischemia secondary to trauma or dissection were excluded.
Severity of ischemia was assessed according to Rutherford’s
clinical categories of ALI.7 If Rutherford categorization
was not clearly reported in the patient’s chart, it was
derived by two authors on the basis of the reported sen-
sory/motor affection and its severity as well as the presence
or absence of Doppler signals on pedal vessels, tissue loss,
rigor, or gangrene on presentation. Patients without
reported Rutherford categorization and those missing
one or more criteria for the proper categorization were
classiﬁed as “unknown severity.” The pedal runoff was eval-
uated angiographically at the initiation and completion of
thrombolysis by assessing the patency of the dorsalis pedis,
posterior tibial, and peroneal collateral vessels in the foot.
Procedures. For the purpose of analysis, patients were
segregated into the ER and OR groups according to the
type of the procedure needed to treat the ﬁrst acute
ischemic incident during the study period. Excluding tech-
nical failures requiring crossover, if the initial procedure
was followed by another procedure of a different revascu-
larization type, the latter procedure was considered an
adjuvant treatment and did not disqualify the patient
from the initial categorization.
The choice of the initial revascularization or subsequent
adjuvant treatment was at the operator’s discretion. Howev-
er, the revascularization approach was standardized on the
basis of the ALI etiology (eg, surgical thrombectomy for
atrial ﬁbrillation [AF] patients vs thrombolysis for small-
vessel emboli and thrombosed bypass vein graft or stent in
patients presenting with Rutherford I or II ischemia).
Timing of the revascularization procedure relied mainly on
the severity of ischemia on presentation. Mild degrees of
ischemia allowed a longer time window for basic workup
and patient optimization. All operative notes and imaging
were reviewed for technical details and to assess for thrombus
distribution, response to therapy, and complications.
In general, CDT was conducted with standard wire and
catheter techniques to embed a multisidehole catheter
(Cragg-McNamara; ev3 Endovascular Inc, Plymouth,
Minn; or Unifuse; AngioDynamics, Latham, NY) into the
thrombosed arterial segment. If thrombosis extended to
the tibial vessels, a Katzen infusion wire (Boston Scientiﬁc,
Natick, Mass) was also used as a coaxial system. Recombi-
nant tissue plasminogen activator (rtPA; Genentech, Inc,
San Francisco, Calif) was the sole lytic agent used. A bolusof 2 to 6 mg of rtPA was delivered into the thrombus, fol-
lowed by an infusion at a rate of 0.25 to 1.00mg/h. Unfrac-
tionated heparin was given through the access sheath at a
rate of 500 units/h to prevent pericatheter thrombosis.
Follow-up angiography was typically performed 6 to
12 hours later on the basis of the clinical response.
PMT with the AngioJet catheter (MEDRAD, Inc,
Warrendale, Pa) was more likely to be used in fresh clot
that was less than 2 weeks old, primarily in thrombosed
femoropopliteal stents, or for residual thrombus after
CDT and was typically avoided in tibial vessels. PMT was
initially used in power pulse mode with 6 to 10 mg of
rtPA, then in regular thrombectomy mode after 12 to
15 minutes of dwell time. Adjuvant CDT was performed
on the basis of the presence of residual thrombus.
Outcomes. The end points for analysis were technical
success, incidence of postoperative complications, length of
hospital stay, loss of primary patency, loss of assisted pri-
mary patency, and loss of secondary patency as well as
amputation and mortality rates at 30 days and 1 year. Mor-
tality rates were analyzed on a patient level, but other out-
comes were analyzed on a limb level.
Mortality, incidence of complications, and patency
rates were calculated for all patients for ER and OR,
whereas technical success and amputation rates were calcu-
lated for all patients as well as for patients in each ischemia
severity class. Rates speciﬁc to Rutherford II class were
further stratiﬁed by the cause of ischemia.
Unplanned return to the operating room was reported
as a complication and included any unscheduled return to
the operating room within 30 postoperative days (eg, ampu-
tations, débridement of infected wound, hematoma evacua-
tion, repair of a pseudoaneurysm, delayed fasciotomy, or
another attempt of revascularization).
Because many OR patients did not have preoperative
or completion angiograms, surgical intervention was
considered technically successful when a palpable pulse or
biphasic Doppler signals were detected over at least one
of the pedal vessels at the completion of the procedure.
Return of monophasic Doppler pedal signals after OR pro-
cedures was not necessarily considered a technical success
in this study, unless it was positively ascertained that this
is the patient’s baseline. Loss of pulse or Doppler signals
at any time point after leaving the operating room did
not count as a technical failure but rather signiﬁed the
end of the primary patency of that procedure. For ER pro-
cedures, technical success was achieved when in-line blood
ﬂow was restored to the foot (or to the ankle through a
patent peroneal artery or large collateral vessel) without
requirement for surgical conversion.
Patency rates were calculated for the initial revascular-
ization procedure and according to published descrip-
tions.7 Recognizing the heterogeneity between the two
groups in terms of severity of ischemia on presentation,
the limb-level comparisons of outcomes were restricted
to patients presenting with Rutherford II ischemia.
Statistical analysis. Patient demographics, comorbid-
ities, cause and severity of ischemia, and complications
Table I. Patient characteristics, severity of ischemia, and
indications for intervention
OR group,
No. (%)
ER group,
No. (%) P value
No. of patients 296 147
No. of limbs 326 154
Age, years, mean 6 SD 70.4 6 14.4 65.9 6 15.2 .003a
Male 164 (55.4) 86 (58.5) .54
Smoking
None 150 (50.7) 37 (25.2) <.001
Current 93 (31.4) 66 (44.9) .006
Former 50 (16.9) 42 (28.6) .003
Unknown 3 (1.0) 2 (1.4)
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c2 test and t-test for categorical and intervally scaled vari-
ables, respectively. Patency rates, limb salvage, and survival
were assessed by time-to-event methods, including Kaplan-
Meier estimation and competing risk-regression models.
Multivariate analysis was performed by logistic or Cox
proportional hazard regression models to identify pre-
dictors of technical success, limb loss, loss of patency, and
death. That was done by a full regression model with all
candidate predictors, followed by a stepwise regression
where all predictors with a P < .1 were retained. Variables
of stepwise selection with P < .05 were considered statis-
tically signiﬁcant.Comorbidities
Coronary artery disease 144 (49.0) 79 (55.2) .22
End-stage renal disease/
dialysis
12 (4.1) 6 (4.2) .96
Congestive heart failure 57 (19.4) 28 (19.6) .96
Chronic obstructive
pulmonary disease
86 (29.1) 33 (22.4) .17
AF 114 (38.5) 32 (21.8) .001
Coronary artery bypass
graft
49 (16.6) 37 (25.2) .02
Stroke 48 (16.2) 18 (12.2) .31
Cancer 67 (22.6) 32 (21.8) .92
Hypertension 234 (79.1) 111 (75.5) .73
Dyslipidemia 133 (44.6) 64 (43.5) .98
Rhabdomyolysis 14 (4.7) 1 (.7) .03
Chronic renal
insufﬁciencyb
39 (13.2) 31 (22.0) .02
Diabetes 91 (30.7) 57 (38.8) .06
Cause of ischemiac
Cardiac embolism 86 (26.4) 14 (9.1) <.001
Native artery
thrombosis
93 (28.5) 37 (24.0) .07
Failed stent 32 (9.8) 41 (26.6) <.001
Failed bypass 100 (30.7) 56 (36.4) .21
Prosthetic graftd 80 (80) 25 (44.6) <.001
Vein graftd 10 (10) 29 (51.8) <.001
Unspeciﬁed graft typed 10 (10) 2 (3.6) .15
Thrombosed peripheral
aneurysm
18 (5.5) 6 (3.9) .45
Aortoiliac embolism 14 (4.3) 8 (5.2) .66
Distribution by severity
Rutherford I 4 (1.2) 15 (9.7) <.001
Rutherford IIa 132 (40.5) 108 (70.1) <.001
Rutherford IIb 138 (42.3) 31 (20.1) <.001
Rutherford III 12 (3.7) 0 (0) .003
Unknown 40 (12.3) 0 (0) <.001
AF, Atrial ﬁbrillation; ER, endovascular revascularization; OR, open revas-
cularization; SD, standard deviation.
aLogistic regression of procedure onto age.
bBaseline serum creatinine level >1.2 g/dL.
cSome cases had multiple causes of ischemia.
dPercentages are based on the total failed bypass.RESULTS
Patient population. A total of 154 limbs (147
patients) in the ER group were compared with 326 limbs
(296 patients) in the OR group. Patient characteristics,
severity of ischemia, and indication for intervention are pre-
sented in Table I. ER patients were younger (66 vs
70 years; P ¼ .003) but more likely to be smokers and to
have a history of coronary artery bypass grafting and
chronic renal insufﬁciency. OR patients were more likely to
have AF or rhabdomyolysis on presentation. Otherwise, no
signiﬁcant differences were detected between the two
groups.
Cause and severity of ischemia. There were signiﬁ-
cant differences between the two groups in terms of cause
of ischemia (Table I); cardiac embolism was more common
in the OR group, whereas failed stent was more common
in the ER group. Although presentation with a failed
bypass graft was almost equally prevalent in both groups
(31% in OR vs 36% in ER; P ¼ not signiﬁcant [NS]), 80%
of the failed grafts were prosthetic in the OR group
compared with 45% in the ER group (P < .001), whereas
10% were vein grafts in the OR group compared with 52%
in the ER group (P < .001).
Despite the differences in the number of ischemic limbs
between the two groups in each severity category, the
majority of limbs were classiﬁed on presentation as Ruther-
ford IIa (41% in OR vs 70% in ER; P < .001) or IIb (42%
in OR vs 20% in ER; P < .001; Table I).
Procedures performed. In the OR group, 293
thromboembolectomies were done (144 femoral, 41 popli-
teal or tibial, 37 multilevel, and 71 for thrombosed bypass
grafts) in addition to 107 bypass grafts (54 infrainguinal,
34 inﬂow, and 19 femorofemoral crossover bypass grafts)
and 67 endarterectomies (51 femoral, nine popliteal, three
tibial, three iliac, and one aortic). Hybrid procedures
included 34 combined balloon angioplasty and stenting
(23 iliac, ﬁve superﬁcial femoral, three popliteal, and three
graft stenosis) and 22 balloon angioplasty only (six iliac, six
popliteal, six tibial, three graft stenosis, and one superﬁcial
femoral artery).
In the ER group, 83 limbs received CDT only, 15
received PMT only, and 56 received a combination of
CDT and PMT.Technical success. In the ER group, the mean dura-
tion of lysis was 25.5 hours for CDT and 23.6 hours for
PMT. Thirty limbs in the ER group failed thrombolysis
because of inadequate response in 26 limbs (13 of them
were treated with successful bypass surgery), intraoperative
bleeding events in three limbs, and failure to cross the
thrombosed vessel in one limb. Patients for whom lysis
failed and who were not candidates for bypass surgery
Table II. Technical success rates stratiﬁed by severity
OR group (n ¼ 326) ER group (n ¼ 154)
P valueNo. % No. %
All limbs 287/326 88.04 124/154 80.52 .028
Category I 4/4 100.00 13/15 86.67 .99
Category IIa 129/132 97.73 86/108 79.63 <.001
Category IIb 116/138 84.06 25/31 80.65 .644
Category II (a þ b) 245/270 90.74 111/139 79.86 .002
Failed bypass 75/80 94.94 39/52 75.00 .001
Prosthetic 61/63 96.83 21/24 87.50 .13
Vein 5/7 71.43 16/26 61.54 .99
Failed stent 26/26 100.00 31/38 81.58 .04
Embolism 77/87 88.51 17/21 80.95 .47
Cardiac embolism 66/75 88.00 12/13 92.30 .99
Aortoiliac embolism 11/12 91.67 5/8 62.50 .26
Native artery thrombosis 67/76 88.16 24/26 92.31 .73
Thrombosed peripheral aneurysm 13/15 86.67 2/6 33.33 .031
Category III 4/12 33.33 d d d
ER, Endovascular revascularization; OR, open revascularization.
Table III. Thirty-day and 1-year amputation rates
Amputation rate
OR group ER group
P valueNo. % No. %
30-day
All limbs 44/326 13.50 10/154 6.49 .023
Category II (a þ b) 27/270 10.0 10/139 7.19 .349
Failed stent 2/26 7.69 1/38 2.63 .561
Failed bypass 5/79 6.33 8/52 15.38 .134
Thrombosed peripheral aneurysm 2/15 13.33 1/6 16.67 .999
Embolism 7/87 8.05 0/21 .00 .341
Native artery thrombosis 11/76 14.47 0/26 .00 .061
1-year
All limbs 64/326 19.63 20/154 12.99 .074
Category II (a þ b) 44/270 16.30 18/139 12.95 .371
Failed stent 7/26 26.92 4/38 10.53 .104
Failed bypass 19/79 24.05 12/52 23.08 .898
Thrombosed peripheral aneurysm 2/15 13.33 1/6 16.67 .999
Embolism 7/87 8.05 1/21 4.76 .999
Native artery thrombosis 14/76 18.42 1/26 3.85 .107
ER, Endovascular revascularization; OR, open revascularization.
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with observation, whereas four patients (six limbs) died.
The overall technical success rate was better with OR
(88%) than with ER (81%; P ¼ .028; Table II). The tech-
nical success rate was also improved in limbs treated for
Rutherford II ischemia and was 91% for OR vs 80% for
ER (P ¼ .002). Stratiﬁcation in Rutherford II patients by
the cause of ischemia showed that OR continued to result
in improved technical rates compared with ER when ALI
was caused by failed bypass graft (95% vs 75%; P ¼ .001),
failed stent (100% vs 82%; P ¼ .04), or thrombosed periph-
eral aneurysm (87% vs 33%; P ¼ .031).
Complications. OR was associated with a higher inci-
dence of wound infection (9% vs 0.7%; P < .001), rethrom-
bosis (14.7% vs 1.3%; P < .001), fasciotomy (29.1% vs
7.3%; P < .001), or unplanned return to the operatingroom (25.5% vs 1.3%; P < .001) compared with ER.
Also, OR had a higher incidence of reversible postoperative
acute renal failure (12% vs 4%; P ¼ .005) and new-onset
postoperative hemodialysis (4% vs 0.7%; P ¼ .04) as well
as a more prolonged hospital stay compared with ER
(11.5 6 12 vs 8 6 7 days; P ¼ .002). On the other hand,
ER was associated with a higher incidence of systemic
bleeding events than OR was (5.8% vs 0%; P < .001).
Limb loss and survival. The overall 30-day amputa-
tion rate was signiﬁcantly higher with OR (13.5%) than with
ER (6.5%; P ¼ .02; Table III and Fig 1). Excluding
Rutherford III patients, rates were 11.5% for OR vs 6.5% for
ER (P ¼ .09). Amputation rates speciﬁc to patients pre-
senting with Rutherford II ischemia were comparable be-
tween the two groups (10% for OR vs 7% for ER; P ¼ .35),
and this remained true when stratiﬁed by cause of ischemia
Fig 1. Kaplan-Meier survival curve: Amputation-free survival
(limb-based analysis).
Fig 2. Kaplan-Meier survival curve: Survival analysis (patient-
based analysis).
Fig 3. Kaplan-Meier survival curve: Primary patency (limb-based
analysis).
Fig 4. Kaplan-Meier survival curve: Assisted primary patency
(limb-based analysis).
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ferences were noted between the OR and ER groups in the
overall amputation rates or in rates speciﬁc to Rutherford II
patients as well.
In Rutherford II patients, despite the fact that amputa-
tion rates were comparable between ER and OR, there was
an observed trend toward improved limb salvage at 30 days
and 1 year with ER compared with OR, speciﬁcally in
patients presenting with failed stent or native artery throm-
bosis. In contrast, OR showed a trend toward better limb
salvage at 30 days compared with ER, speciﬁcally for
patients presenting with failed bypass graft.
The overall mortality rates (Fig 2) were signiﬁcantly
lower with ER than with OR at 30 days (5.4% vs 13.2%;
P ¼ .012), 1 year (12.9% vs 33.8%; P < .001), and 2 years
(18.7% vs 40.5%; P < .001).
Patency rates. The mean follow-up time was
14 months (range, 1-92 months). The primary patency
rates were comparable between OR and ER at 1 year (57%
and 51%, respectively; P ¼ .74) and 2 years (48% and 38%,respectively; P ¼ .38). The primary-assisted patency rates
for OR and ER (96% and 100% at 1 year, 92% and 97% at
2 years, respectively; P ¼ NS) and secondary patency rates
(96% and 91% at 1 year, 92% and 89% at 2 years, respec-
tively; P ¼ NS) were also comparable (Figs 3 to 5).
Predictors of technical success. Predictors of technical
success were sought to help in the clinical decision making
based on patient presentation, etiology of ischemia, and pa-
tient anatomy. Multivariable analysis of all the study patients
showed that ER (odds ratio [OR], 0.2; P¼ .001) and Ruth-
erford III ischemia on presentation (OR, <0.01; P ¼ .001)
were less likely to achieve technical success compared with
OR and less severe ischemia (Table IV). On the other
hand, the presence of any patent pedal outﬂow was a signif-
icant predictor for technical success (OR, 6.0, P < .001 for
one vessel; OR, 6.9 andP¼ .002 for two vessels; OR, 7.7 and
P ¼ .012 for three vessels). Other predictors used in the
regressionmodel, such as comorbidities, etiology of ischemia,
prosthetic bypass, vein bypass, or failed stent, were not sig-
niﬁcant predictors of the technical outcome.
Table IV. Predictors of technical success
Variable OR 95% CI P value
ER 0.19 0.072-0.513 .001
Comorbidities
Age 1.03 1.005-1.058 .019
Cancer 0.44 0.181-1.076 .072
Pedal outﬂowa .001
1 vessel 5.95 2.342-15.127 <.001
2 vessels 5.88 1.917-18.060 .002
3 vessels 7.69 1.554-38.109 .012
Severity of ischemiab .001
Category IIa 0.60 0.101-3.571 .575
Category IIb 0.24 0.035-1.581 .137
Category III <0.01 <0.001-0.103 .001
CI, Conﬁdence interval; ER, endovascular revascularization; OR, odds
ratio.
aReference category is zero.
bReference category is Rutherford I category.
Table V. Predictors of loss of primary patency
Variable HR 95% CI P value
Endovascular intervention 0.850 0.560-1.290 .430
Comorbidities
CAD 1.580 1.110-2.250 .020
Cause of ischemia
Failed stent 2.410 1.571-3.699 <.001
Failed bypass .004
Prosthetic 1.686 1.131-2.514 .010
Vein 2.433 1.263-4.688 .010
Severity of ischemiaa .002
Category IIa 0.615 0.289-1.307 .210
Category IIb 0.642 0.290-1.423 .280
Category III 6.182 1.497-25.522 .020
CAD, Coronary artery disease; CI, conﬁdence interval; HR, hazard ratio.
aReference category is Rutherford I category.
Table VI. Predictors of limb loss
Variable HR 95% CI P value
Endovascular intervention 1.061 0.624-1.803 .827
Comorbidities
ESRD/dialysis 2.349 0.890-6.200 .085
CAD 1.970 1.208-3.214 .007
CHF 0.482 0.242-0.959 .037
Severity of ischemiaa <.001
Category IIa 1.179 0.272-5.108 .826
Category IIb 3.418 0.792-14.742 .099
Category III 19.305 3.699-100.760 <.001
CAD, Coronary artery disease; CHF, congestive heart failure; CI, conﬁ-
dence interval; ESRD, end-stage renal disease; HR, hazard ratio.
aReference category is Rutherford I category.
Fig 5. Kaplan-Meier survival curve: secondary patency (limb-
based analysis).
Table VII. Predictors of mortality
Variable HR 95% CI P value
Endovascular intervention 0.687 0.447-1.055 .086
Comorbidities
Age 1.031 1.018-1.043 <.001
Cancer 1.646 1.160-2.336 .005
ESRD/dialysis 7.278 3.577-14.809 <.001
CRI 1.449 0.973-2.157 .068
COPD 1.609 1.154-2.245 .005
Severity of ischemiaa .001
Category IIa 5.973 0.772-46.237 .087
Category IIb 7.995 1.030-62.078 .047
Category III 38.675 4.617-323.971 .001
CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease;
CRI, chronic renal insufﬁciency; ESRD, end-stage renal disease; HR, haz-
ard ratio.
aReference category is Rutherford I category.
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ischemia on presentation was a strong predictor for loss of
primary patency (hazard ratio [HR], 6.2; P ¼ .02). Other
signiﬁcant predictors included failed stents and failed pros-
thetic or vein bypass grafts as causes of ischemia
(Table V). Irrespective of the severity of ischemia on
presentation, neither the type of revascularization nor the
number of pedal outﬂow vessels was found to predict for the
loss of primary patency.
Predictors of limb loss. The only signiﬁcant predic-
tors for limb loss were presentation with Rutherford III
ischemia (HR, 19.3; P < .001) and coronary artery disease
(HR, 1.97; P ¼ .007; Table VI). In all study patients, the
type of revascularization (ER vs OR) and the cause of
ischemia were not predictors for limb loss.
Predictors of mortality. Factors that conferred the
highest risk for overall mortality included end-stage renal
disease and advanced ischemia (Rutherford IIb and III;
Table VII). Age, cancer, and chronic obstructive pulmo-
nary disease were also associated with a signiﬁcant risk for
mortality.DISCUSSION
The beneﬁts of thrombolysis as an initial treatment of
ALI were reported in a number of trials comparing OR
and ER of acutely ischemic limbs.1,2,8 However, the het-
erogeneity between those studies made it difﬁcult to
directly compare the treatment outcomes or to apply
them to current clinical practice.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 1 Taha et al 153We also found signiﬁcant differences in our study be-
tween the OR and ER groups in terms of prevalence of
the different causes of ischemia as well as the severity of
ALI on presentation. We therefore focused in our limb-
level comparisons on patients presenting with Rutherford
IIa or IIb categories and on subgroup analyses of individual
causes of ischemia to have comparable groups. Indeed,
patients presenting with Rutherford II (IIa and IIb)
ischemia composed the majority of the ischemic limbs in
our study (82.8% of the OR group vs 90.2% of the ER
group), allowing us to compare the treatment outcomes.
In this study, the overall 30-day amputation rates were
lower in the ER group than in the OR group (6.5% vs
13.5%; P ¼ .023), and these were similar to the amputation
rates previously reported in the Surgery vs Thrombolysis for
Ischemia of the Lower Extremity (STILE) trial (5.7% and
17.9%, respectively).1 At 1 year, the overall amputation rate
in the ER group (13%) was comparable to that reported in
the Thrombolysis or Peripheral Arterial Surgery (TOPAS)
trial (15%)2; however, the amputation rate in our OR group
was higher (19.6%) than the rate for OR reported in the
TOPAS (13.1%)2 or Rochester (18%)8 trial. This can be
explained by the fact that both trials excluded patients with
advanced limb ischemia, whereas some of our OR limbs
were treated for Rutherford III ischemia.Moreover, 40 limbs
(12.3%) of the OR group could not be classiﬁed into any
Rutherford category because of the retrospective nature of
the analysis or the presence of a coexisting condition that pre-
vented categorization (eg, remote history of paralysis,
compromised level of consciousness, patients transferred un-
der anesthesia). Some of those ischemic limbs of unclassiﬁed
severity could have had Rutherford III ischemia, which con-
fers a signiﬁcantly higher amputation rate.
On the other hand, the amputation rates in patients
treated for Rutherford II ischemia were comparable be-
tween the ER and OR groups at 30 days (7% vs 10%,
respectively; P ¼ NS) and at 1 year (13% vs 16%, respec-
tively; P ¼ NS). This is also comparable to the 1-year
amputation rates of the thrombolysis and surgical arms in
both the TOPAS (15% vs 13.1%)2 and Rochester (18% vs
18%)8 trials. In agreement with this observation, the multi-
variate analysis in the present study showed that the type of
revascularization with ER or OR did not predict for limb
loss in patients presenting with Rutherford II ischemia,
suggesting that either approach can achieve similar limb
salvage in general.
However, this general observation may not hold true in
comparing limb salvage on the basis of the etiology of limb
ischemia. Consequently, we further stratiﬁed the amputa-
tion rates of Rutherford II patients by the etiology of
ischemia. Although this stratiﬁcation failed to show a sig-
niﬁcant difference between ER and OR (at 30 days or
1 year), ER showed a trend toward better limb salvage
compared with OR, speciﬁcally in patients with failed stent
(amputation rate of 2.6% vs 7.7% at 30 days, P ¼ .561; and
10.5% vs 26.9% at 1 year, P ¼ .104) or native artery throm-
bosis (amputation rate of 0% vs 14.5% at 30 days, P ¼ .061;
3.9% vs 18.4% at 1 year, P ¼ .107). In contradistinction,the STILE trial showed a higher rate of amputation with
thrombolysis for nonembolic native artery occlusion
compared with surgery.9 However, this may reﬂect out-
comes of subacute ischemia because the majority of STILE
patients had chronic symptoms (44% with symptoms for
1 month or more and 26% for 2 months or more vs 30%
with symptoms within 14 days). The lack of agreement be-
tween those results and ours may imply that ER can be
more useful in the setting of acute arterial occlusion.
In patients with failed bypass grafts, OR showed a favor-
able trend for limb salvage at 30 days (amputation rate of
6.3% vs 15.4%; P ¼ .0134), but this was not maintained at
1 year (1-year amputation rate of 24% vs 23%; P ¼ .898).
In contrast, a post-study analysis of STILEpatientswith acute
graft occlusion showed that thrombolysis had a signiﬁcantly
reduced 1-year amputation rate compared with surgery.10
In that analysis, thrombolysis was found to bemost beneﬁcial
in acutely occluded vein grafts, whereas thrombolysis of
occluded prosthetic grafts was associated with increased
morbidity.
In this study, vein grafts represented only 25% of all
graft occlusions. The limited frequency of vein graft occlu-
sion, which might derive better outcomes with thromboly-
sis, may have contributed to the reduced limb salvage with
ER relative to OR in patients with failed bypass. Although
the beneﬁt of OR was not maintained in our study, the
observed short-term beneﬁt of OR suggests that surgical
revascularization may be the preferred option for the treat-
ment of ALI secondary to failed bypass grafts, at least for
patients with failed prosthetic grafts.
In addition, whereas the proportion of patients pre-
senting with native artery thrombosis and vein or prosthetic
graft occlusion was equally distributed in patients treated
with ER (24%, 16%, and 19%, respectively), this was not
the case for patients treated with OR (29%, 3%, and 25%,
respectively). As such, this allowed a reliable comparison
between the amputation rates associated with those three
causes of ischemia in patients treated with ER, which
showed that risk of limb loss was not different by the
type of vessel.4 This comparison was not undertaken in
patients treated with OR, given the limited representation
of patients with failed vein bypass graft.
Limb ischemia fromAF represented26%ofORand9%of
ER in all patients (29% and 9% inRutherford II patients). The
higher prevalence of AF embolism treated with OR might
have biased the overall amputation rates, given the generally
simpler operation required for revascularization. As such,
cause-speciﬁc rates were calculated to minimize such a bias,
allowing us to estimate amputation rates for each category
(failed stent, failed bypass graft, native artery thrombosis).
What was interesting to note, however, is that patients pre-
senting with an AF embolus and treated with ER were able
to achieve adequate technical success and limb salvage with
minimal complications, which goes against the perceived
notion that the organized nature of such emboli makes
them less likely to respond to lytic therapy. ERmay therefore
be a viable option for patients with an AF embolus who are at
high risk for surgery or have hostile anatomy.
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complications, there was also a signiﬁcantly higher mortal-
ity with OR at all time points. Although the overall 30-day
mortality rate in ER patients (5.44%) is comparable to that
in the STILE1 and TOPAS2 trials (4.3% and 8.8%, respec-
tively), the corresponding rate in the OR group (13.18%) is
remarkably higher than in the STILE (5.1%) or TOPAS
(5.9%) trials. This might be attributed to the higher preva-
lence of comorbidities in our patient population, with a
higher prevalence of coronary artery disease, hypertension,
congestive heart failure, cancer, and hypercholesterolemia.
What is clear is that the perioperative morbidity and mor-
tality with OR continue to be high in contemporary prac-
tice for patients treated for ALI, despite aggressive medical
management and cardiovascular risk reduction strategies.
This has to be considered in the decision-making algo-
rithm, perhaps favoring ER despite its lower technical suc-
cess but improved safety proﬁle and similar limb salvage
rate compared with OR.
Another important observation is that the only consis-
tent predictor for all adverse outcomes in our study was the
presentation with irreversible limb ischemia (Rutherford
III ischemia). As expected, the technical success in this
group of patients was poor, and even when the revascular-
ization was initially successful, the increased risk of loss of
primary patency, major amputation, and death observed
negates any likelihood of salvaging a functional limb in
those patients. Consequently, for patients presenting with
advanced Rutherford III ALI, any type of revascularization
might be futile or even harmful, given the life-threatening
consequences of the reperfusion syndrome, suggesting that
a primary amputation should be considered a potentially
safer alternative.
This study, being retrospective, has important limita-
tions that can affect the completeness of the available peri-
operative and follow-up data. In addition, we tried to
mitigate the pitfall of the uneven distribution of the pa-
tients among the severity groups by focusing on Ruther-
ford II patients in our comparisons. This yielded an even
distribution of Rutherford IIa and IIb patients treated
with OR but a higher number of IIa patients treated
with ER, which could still introduce a selection bias.
Although this subgroup analysis was aimed at analyzing
comparable groups, it resulted in exclusion of patients
with extremes of ischemic class on presentation. This, how-
ever, mirrors the strategy used in randomized trials for ALI
that included only patients with Rutherford II ischemia.
CONCLUSIONS
Despite the limitations, we believe that the large sam-
ple size, the subgroup analyses, and the regression models
allow us to conclude that OR as an initial treatment of ALI
results in improved technical success rates in patients with
Rutherford II ischemia, especially when it is caused by a
failed stent or bypass graft. This was at the expense of a
higher mortality rate compared with ER, without the
added advantage of improved patency or limb salvage at
30 days and at 1 year.In patients with Rutherford II ischemia secondary to
stent failure or native artery thrombosis, the observed trend
toward improved limb salvage with thrombolysis (at
30 days and 1 year) might suggest that ER may be consid-
ered the initial treatment for this particular group of
patients. In contrast, patients with failed bypass grafts had
a trend toward improved limb salvage with OR, which
might suggest that surgery should be the preferred initial
treatment for those patients. However, the decision be-
tween OR and ER has to be individualized on the basis
of not only the class and etiology of ischemia but, more
important, the patient’s comorbidities, given the increased
mortality associated with open repair.
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